{"filing":{"accession_number":"0001193125-26-239535","cik":"0001607678","ticker":"VKTX","company_name":"Viking Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-26","report_date":null,"primary_document":"vktx-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1607678/000119312526239535/vktx-20260519.htm"},"events":[{"id":9045,"run_id":7941,"accession_number":"0001193125-26-239535","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Viking Therapeutics' 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing reports results on three proposals: election of Class II directors (J. Matthew Singleton and S. Kathryn Rouan, Ph.D.), ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies and passage of all three proposals constitute material shareholder actions that affect corporate governance and oversight.","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-05-26","form":"8-K","submitted_at":null,"items":[{"id":1530,"accession_number":"0001193125-26-239535","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Viking Therapeutics' 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing reports results on three proposals: election of Class II directors (J. Matthew Singleton and S. Kathryn Rouan, Ph.D.), ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies and passage of all three proposals constitute material shareholder actions that affect corporate governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:12:52.360147+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1530,"accession_number":"0001193125-26-239535","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Viking Therapeutics' 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing reports results on three proposals: election of Class II directors (J. Matthew Singleton and S. Kathryn Rouan, Ph.D.), ratification of CBIZ CPAs P.C. as independent auditor, and advisory approval of named executive officer compensation. The detailed vote tallies and passage of all three proposals constitute material shareholder actions that affect corporate governance and oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-27T02:12:52.360147+00:00","company_name":"Viking Therapeutics, Inc.","ticker":"VKTX","filing_date":"2026-05-26"}]}